RxDoctor Payments Data

Jeffrey Johnson, DPM

Podiatrist · Rumford, MENPI 1295899672

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Organogenesis Inc. accounts for 81.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,553 and has fallen 89.8% since, to $159 in 2025.

$1,958in general payments, 2019–2025

Across 35 payments — averaging $55.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$2K
  • 4web, Inc.$147
  • Paratek Pharmaceuticals, Inc.$144
  • Hydrofera LLC$29
  • Mimedx Group, Inc.$22
  • Advanced Oxygen Therapy Inc.$15

What the payments were for

  • Speaking & faculty fees$1256%
  • Travel & lodging$1,00851%
  • Food & beverage$82542%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,958 in reported general payments places this provider in the 65th percentile of 20 podiatrist providers in Maine.

See all podiatrist providers in Maine

Medicare billing

Part B allowed, 2024
$59,158
Medicare patients
337
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate19$274
Cephalexin22$263

Paid to pharmacies, not to this prescriber.

Other podiatrist in Rumford

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →